[go: up one dir, main page]

WO2000030671A3 - Nf-at mediates cardiac hypertrophy, methods and reagents related thereto - Google Patents

Nf-at mediates cardiac hypertrophy, methods and reagents related thereto Download PDF

Info

Publication number
WO2000030671A3
WO2000030671A3 PCT/US1999/027862 US9927862W WO0030671A3 WO 2000030671 A3 WO2000030671 A3 WO 2000030671A3 US 9927862 W US9927862 W US 9927862W WO 0030671 A3 WO0030671 A3 WO 0030671A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
cardiac hypertrophy
reagents related
mediates cardiac
mediates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1999/027862
Other languages
French (fr)
Other versions
WO2000030671A9 (en
WO2000030671A2 (en
Inventor
Gerald R Crabtree
Jeffrey P Northrop
Steffan N Ho
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University
Priority to JP2000583554A priority Critical patent/JP2002530349A/en
Priority to IL14329799A priority patent/IL143297A0/en
Priority to CA002352599A priority patent/CA2352599A1/en
Priority to EP99967129A priority patent/EP1131086A2/en
Publication of WO2000030671A2 publication Critical patent/WO2000030671A2/en
Publication of WO2000030671A3 publication Critical patent/WO2000030671A3/en
Publication of WO2000030671A9 publication Critical patent/WO2000030671A9/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8103—Exopeptidase (E.C. 3.4.11-19) inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The invention is a method for treating cardiac hypertrophy, or other preventing other growth of cardiac and vascular tissue, through the use of NF-AT antagonists.
PCT/US1999/027862 1998-11-24 1999-11-23 Nf-at mediates cardiac hypertrophy, methods and reagents related thereto Ceased WO2000030671A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2000583554A JP2002530349A (en) 1998-11-24 1999-11-23 NF-AT mediated cardiac hypertrophy and related methods and reagents
IL14329799A IL143297A0 (en) 1998-11-24 1999-11-23 Nf-at mediates cardiac hypertrophy, methods and reagents related thereto
CA002352599A CA2352599A1 (en) 1998-11-24 1999-11-23 Nf-at mediates cardiac hypertrophy, methods and reagents related thereto
EP99967129A EP1131086A2 (en) 1998-11-24 1999-11-23 Nf-at mediates cardiac hypertrophy, methods and reagents related thereto

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19897798A 1998-11-24 1998-11-24
US09/198,977 1998-11-24

Publications (3)

Publication Number Publication Date
WO2000030671A2 WO2000030671A2 (en) 2000-06-02
WO2000030671A3 true WO2000030671A3 (en) 2000-11-09
WO2000030671A9 WO2000030671A9 (en) 2001-05-17

Family

ID=22735695

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/027862 Ceased WO2000030671A2 (en) 1998-11-24 1999-11-23 Nf-at mediates cardiac hypertrophy, methods and reagents related thereto

Country Status (5)

Country Link
EP (1) EP1131086A2 (en)
JP (1) JP2002530349A (en)
CA (1) CA2352599A1 (en)
IL (1) IL143297A0 (en)
WO (1) WO2000030671A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6687428B2 (en) 2000-09-21 2004-02-03 Tera Op (Usa) Inc. Optical switch
US20130183686A1 (en) * 2008-11-11 2013-07-18 Donna Davidovich Method of evaluating immunosuppression

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993004203A1 (en) * 1991-08-22 1993-03-04 The Board Of Trustees Of The Leland Stanford Jr. University Screening methods for immunosuppressive agents
WO1994015964A1 (en) * 1993-01-15 1994-07-21 Dana-Farber Cancer Institute, Inc. NF-ATp, A T LYMPHOCYTE DNA-BINDING PROTEIN
WO1995005389A1 (en) * 1993-08-18 1995-02-23 The Board Of Trustees Of The Leland Stanford Junior University Sequence-specific glycoconjugate transcriptional antagonists
WO1995008554A1 (en) * 1993-09-20 1995-03-30 The Board Of Trustees Of The Leland Stanford Junior University Nf-at polypeptides and polynucleotides
WO1996026959A1 (en) * 1995-03-02 1996-09-06 Tularik, Inc. Human transcription factors and binding assays
WO1999019471A1 (en) * 1997-10-16 1999-04-22 Board Of Regents, The University Of Texas System Models and treatments for cardiac hypertrophy in relation with nf-at3 function
WO1999040930A1 (en) * 1998-02-12 1999-08-19 Center For Blood Research, Inc. Specific inhibitors of nfat activation by calcineurin and their use in treating immune-related diseases

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993004203A1 (en) * 1991-08-22 1993-03-04 The Board Of Trustees Of The Leland Stanford Jr. University Screening methods for immunosuppressive agents
WO1994015964A1 (en) * 1993-01-15 1994-07-21 Dana-Farber Cancer Institute, Inc. NF-ATp, A T LYMPHOCYTE DNA-BINDING PROTEIN
WO1995005389A1 (en) * 1993-08-18 1995-02-23 The Board Of Trustees Of The Leland Stanford Junior University Sequence-specific glycoconjugate transcriptional antagonists
WO1995008554A1 (en) * 1993-09-20 1995-03-30 The Board Of Trustees Of The Leland Stanford Junior University Nf-at polypeptides and polynucleotides
WO1996026959A1 (en) * 1995-03-02 1996-09-06 Tularik, Inc. Human transcription factors and binding assays
WO1999019471A1 (en) * 1997-10-16 1999-04-22 Board Of Regents, The University Of Texas System Models and treatments for cardiac hypertrophy in relation with nf-at3 function
WO1999040930A1 (en) * 1998-02-12 1999-08-19 Center For Blood Research, Inc. Specific inhibitors of nfat activation by calcineurin and their use in treating immune-related diseases

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BEALS C R ET AL: "Nuclear export of NF-ATc enhanced by glycogen synthase kinase-3.", SCIENCE, vol. 275, no. 5308, 28 March 1997 (1997-03-28), pages 1930 - 1933, XP002140286 *
DE LA POMPA JL ET AL: "Role of the NF-ATc transcription factor in morphogenesis of cardiac valves and septum.", NATURE, vol. 392, no. 6672, 12 March 1998 (1998-03-12), pages 182 - 186, XP002140287 *
SUSSMAN M A ET AL: "Prevention of cardiac hypertrophy in mice by calcineurin inhibition.", SCIENCE, vol. 281, no. 5383, 11 September 1998 (1998-09-11), pages 1690 - 1693, XP002140285 *

Also Published As

Publication number Publication date
JP2002530349A (en) 2002-09-17
IL143297A0 (en) 2002-04-21
WO2000030671A9 (en) 2001-05-17
EP1131086A2 (en) 2001-09-12
CA2352599A1 (en) 2000-06-02
WO2000030671A2 (en) 2000-06-02

Similar Documents

Publication Publication Date Title
EP2319527A3 (en) BAFF, inhibitors thereof and their use in the modulation of the B-cell response
WO2003041602A3 (en) Tissue ablation device and methods of using
AU3865899A (en) Apparatus and methods for the penetration of tissue, and the creation of an opening therein
ZA979820B (en) Methods for draping surgical incision sites.
EP1121055A4 (en) Device and method for suturing blood vessels and the like
ZA9710219B (en) Systems, methods, and instruments for minimally invasive surgery.
ZA964886B (en) Suture guard for prosthetic heart valve.
FI874127L (en) Surgical suture or ligature having a bioabsorbable coating and method for making the same
EP0796627A3 (en) Treatment of aldehyde-fixed tissue
EP1030598A4 (en) Surgical template assembly and method for drilling and installingdental implants
AU4709699A (en) Single suture biological tissue aortic stentless valve
ID25764A (en) FTALAMIDA DAMAGES, OR ITS SALT FOR AGROHOLTICULTURE INSECTICIDE, AND THE METHOD OF USE
ZA973562B (en) Surgical glove retainer.
AU1749700A (en) Methods and articles for regenerating living tissue
AU1951697A (en) The preservation of tissue during removal, storage and implantation
CA2169381A1 (en) Enhanced cross-linking of natural tissues
HK1039342A1 (en) Connective tissue growth factor (ctgf) and methods of use
EP1441749A4 (en) STENT OR VASCULAR GRAFT COATED OR IMPREGNATED WITH TYROSINE KINASE INHIBITORS AND METHOD OF USE THEREOF
WO2001029189A3 (en) Synthetic substrate for tissue formation
ZA991220B (en) Method of treating heart failure.
PL350920A1 (en) Substituted 3-cyano-[1.7], [1.5], and [1.8]-naphthyridine inhibitors of tyrosine kinases
EP1430843A3 (en) Drill apparatus for embedding an implant in bone
ZA200004854B (en) Treatment of cardiac hypertrophy.
CA2336375A1 (en) Salt-stable modified starch
EP0635263A3 (en) Angiotensin (AII) antagonists as inhibitors of the growth of adipose tissue.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): CA JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): CA JP US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

AK Designated states

Kind code of ref document: C2

Designated state(s): CA JP US

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

COP Corrected version of pamphlet

Free format text: PAGE 7, DESCRIPTION, REPLACED BY A NEW PAGE 7; PAGES 1/26-26/26, DRAWINGS, REPLACED BY NEW PAGES 1/30-30/30; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

WWE Wipo information: entry into national phase

Ref document number: 143297

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 2352599

Country of ref document: CA

Ref country code: CA

Ref document number: 2352599

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 583554

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1999967129

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1999967129

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1999967129

Country of ref document: EP